# LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients

> **NCT02840136** · NA · TERMINATED · sponsor: **University Ghent** · enrollment: 40 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Piperacillin-tazobactam combination product
- **DRUG:** Meropenem
- **DRUG:** Ceftazidime

## Key facts

- **NCT ID:** NCT02840136
- **Lead sponsor:** University Ghent
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2017-09-01
- **Final completion:** 2017-09-01
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Lack of staff
- **Last updated:** 2021-12-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840136, "LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02840136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*